Why Spinogenix’s tazbentetol data could reshape glaucoma and diabetic retinopathy research
Retinal disease care still targets drivers. Spinogenix is testing whether synaptic regeneration can protect vision when damage continues.
Can Everads Injector change how ophthalmology drugs reach the back of the eye?
Retina drugs are improving, but delivery remains the bottleneck. Everads Therapy is testing whether suprachoroidal access can change that.
Can Sydnexis’ SYD-101 data sharpen the case for low-dose atropine in fast-progressing pediatric myopia?
Pediatric myopia is rising fast, but U.S. drug options remain thin. Sydnexis’ SYD-101 data may sharpen the regulatory race.